Yezan Munther Haddadin - Net Worth and Insider Trading

Yezan Munther Haddadin Net Worth

The estimated net worth of Yezan Munther Haddadin is at least $10,350 dollars as of 2024-12-02. Yezan Munther Haddadin is the Director of Outlook Therapeutics Inc and owns about 5,049 shares of Outlook Therapeutics Inc (OTLK) stock worth over $10,350. Details can be seen in Yezan Munther Haddadin's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Yezan Munther Haddadin has not made any transactions after 2024-03-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Yezan Munther Haddadin

To

Yezan Munther Haddadin Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Yezan Munther Haddadin owns 1 companies in total, including Outlook Therapeutics Inc (OTLK) .

Click here to see the complete history of Yezan Munther Haddadin’s form 4 insider trades.

Insider Ownership Summary of Yezan Munther Haddadin

Ticker Comapny Transaction Date Type of Owner
OTLK Outlook Therapeutics Inc 2024-03-28 director

Yezan Munther Haddadin Latest Holdings Summary

Yezan Munther Haddadin currently owns a total of 1 stock. Yezan Munther Haddadin owns 5,049 shares of Outlook Therapeutics Inc (OTLK) as of March 28, 2024, with a value of $10,350.

Latest Holdings of Yezan Munther Haddadin

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
OTLK Outlook Therapeutics Inc 2024-03-28 5,049 2.05 10,350

Holding Weightings of Yezan Munther Haddadin


Yezan Munther Haddadin Form 4 Trading Tracker

According to the SEC Form 4 filings, Yezan Munther Haddadin has made a total of 5 transactions in Outlook Therapeutics Inc (OTLK) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Outlook Therapeutics Inc is the acquisition of 1,882 shares on March 28, 2024, which cost Yezan Munther Haddadin around $22,242.

Insider Trading History of Yezan Munther Haddadin

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Yezan Munther Haddadin Trading Performance

GuruFocus tracks the stock performance after each of Yezan Munther Haddadin's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Yezan Munther Haddadin is 23.85%. GuruFocus also compares Yezan Munther Haddadin's trading performance to market benchmark return within the same time period. The performance of stocks bought by Yezan Munther Haddadin within 3 months outperforms 3 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Yezan Munther Haddadin's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Yezan Munther Haddadin

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -1.96 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -3.72 LIMIT LIMIT LIMIT LIMIT LIMIT

Yezan Munther Haddadin Ownership Network

Ownership Network List of Yezan Munther Haddadin

No Data

Ownership Network Relation of Yezan Munther Haddadin

Insider Network Chart

Yezan Munther Haddadin Owned Company Details

What does Outlook Therapeutics Inc do?

Who are the key executives at Outlook Therapeutics Inc?

Yezan Munther Haddadin is the director of Outlook Therapeutics Inc. Other key executives at Outlook Therapeutics Inc include CFO and Secretary Lawrence A Kenyon , Chief Commercial Officer Jeff Evanson , and Chief Operating Officer Terry Dagnon .

Outlook Therapeutics Inc (OTLK) Insider Trades Summary

Over the past 18 months, Yezan Munther Haddadin made 1 insider transaction in Outlook Therapeutics Inc (OTLK) with a net purchase of 1,882. Other recent insider transactions involving Outlook Therapeutics Inc (OTLK) include a net purchase of 62,484 shares made by Jeff Evanson , a net purchase of 5,000 shares made by Lawrence A Kenyon ,

In summary, during the past 3 months, insiders sold 0 shares of Outlook Therapeutics Inc (OTLK) in total and bought 5,000 shares, with a net purchase of 5,000 shares. During the past 18 months, 0 shares of Outlook Therapeutics Inc (OTLK) were sold and 10,006 shares were bought by its insiders, resulting in a net purchase of 10,006 shares.

Outlook Therapeutics Inc (OTLK)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Outlook Therapeutics Inc Insider Transactions

No Available Data

Yezan Munther Haddadin Mailing Address

Above is the net worth, insider trading, and ownership report for Yezan Munther Haddadin. You might contact Yezan Munther Haddadin via mailing address: Zahran Street, 7th Circle Zahran Plaza, 4th Floor, Po Box 142904, Amman M2 11844.

Discussions on Yezan Munther Haddadin

No discussions yet.